Acetylurea represents a foundational chemical entity at the crossroads of classical organic synthesis, medicinal chemistry, and neuropharmacology. As a monosubstituted acylurea derivative, this compound serves both as a structural prototype for open-chain anticonvulsants and as a versatile building block in heterocyclic chemistry. Understanding its molecular architecture, historical development, biochemical pathways, and pharmacological implications provides profound insight into how simple modifications of urea can fundamentally alter physiological and chemical reactivity.
Acetylurea
1. Concise Definition
Acetylurea, chemically designated as N-carbamoylacetamide or ethanoylurea (chemical formula: C3H6N2O2), is an organic compound belonging to the class of acylureas, characterized by an acetyl moiety covalently linked to one of the nitrogen atoms of a urea backbone. In pure form, it exists as a colorless to white crystalline solid with a relatively high melting point, exhibiting modest solubility in cold water and elevated solubility in hot water and polar organic solvents.
In medicinal chemistry and pharmacology, acetylurea constitutes the fundamental scaffold from which clinically significant open-chain anticonvulsants—most notably phenacemide (phenylacetylurea) and pheneturide (ethylphenylacetylurea)—were derived during the mid-twentieth century. Although parent acetylurea possesses limited intrinsic therapeutic efficacy on its own, its molecular framework bridges the gap between simple aliphatic amides and cyclic antiepileptic agents such as hydantoins and barbiturates. Its structural simplicity also makes it a valuable model substrate in thermodynamic, kinetic, and crystallographic investigations of hydrogen bonding networks and peptide-like bond behavior.
2. Etymology & Linguistic Origin
The term acetylurea is a systematic chemical portmanteau derived from two distinct linguistic and chemical roots: acetyl and urea. The word acetyl traces back to the Latin acetum, meaning "vinegar," combined with the Greek suffix hyle (υλη), traditionally used in nineteenth-century chemistry to denote "matter," "substance," or "radical." This term was originally coined by the German chemist Justus von Liebig in the 1830s to describe the radical of acetic acid.
The root urea is derived from the French urée, which in turn originates from the Ancient Greek ouron (ουρον), meaning "urine." French chemist Hilaire-Marin Rouelle first isolated urea from urine in 1773, and Friedrich Wöhler famously synthesized it from inorganic ammonium cyanate in 1828. When organic chemists in the mid-to-late nineteenth century began systematically substituting acyl groups onto the amine terminals of urea, the resulting derivatives were termed acylureas, with the simplest acetic derivative becoming known universally as acetylurea (German: Acetylharnstoff; French: acétylurée).
3. Pronunciation & Grammatical Form
The term is phonetically transcribed in the International Phonetic Alphabet (IPA) as /æs.ɪ.tÉ™l.jʊəɪ.rɪ.É™/ or /É™.siË.tÉ™l.jʊəɪ.rɪ.É™/ in American English, and /æs.ɪ.taŠl.jʊəɪ.riË.É™/ in British English.
Grammatically, acetylurea functions as an uncountable proper chemical noun. In contemporary nomenclature established by the International Union of Pure and Applied Chemistry (IUPAC), the compound is systematically indexed as N-carbamoylacetamide, although "acetylurea" and "1-acetylurea" remain widely accepted semi-systematic names in academic, clinical, and industrial literature. Common synonyms and laboratory designations include ethanoylurea, acetocarbamide, N-acetylurea, and acetylcarbamide.
4. Detailed Conceptual Explanation
From a structural perspective, acetylurea embodies the convergence of an amide and a urea functionality within a single, low-molecular-weight framework. The molecule comprises an acetyl group (–C(=O)CH3) bound to one of the nitrogen atoms of urea (–NH–C(=O)–NH2). This spatial arrangement establishes a planar or near-planar dicarbonyl architecture where two carbonyl oxygens flanking a secondary amide nitrogen create an imide-like electronic environment. Consequently, the central secondary nitrogen atom experiences significant electron withdrawal due to the resonance delocalization of its lone pair into both adjacent carbonyl groups, rendering its attached hydrogen atom noticeably more acidic than those of unsubstituted urea.
The electronic distribution of acetylurea profoundly impacts its supramolecular behavior and solid-state packing. The molecule contains multiple classical hydrogen bond donors (the primary –NH2 group and the secondary –NH– group) and multiple hydrogen bond acceptors (the urea carbonyl oxygen and the acetyl carbonyl oxygen). In crystalline form, acetylurea forms an intricate, highly stable network of intermolecular hydrogen bonds, typically organizing into antiparallel dimers and linear ribbon arrays. This robust crystal lattice accounts for its surprisingly elevated melting point (approximately 218 °C to 220 °C), which is substantially higher than that of many other monosubstituted aliphatic amides of comparable molecular mass.
In aqueous solution, acetylurea displays unique thermodynamic and kinetic properties. It is amphiprotic in extreme environments but remains largely non-ionized across physiological pH ranges (pH 2.0 to 8.0). However, the polarization of its carbonyl groups makes it susceptible to both acid- and base-catalyzed hydrolytic cleavage. Under vigorous acidic conditions, it decomposes to form acetic acid, carbon dioxide, and ammonium ions, whereas alkaline hydrolysis typically yields acetate salts, ammonia, and carbonate. This susceptibility to nucleophilic attack at the acetyl versus carbamoyl carbonyl centers has made acetylurea a classic mechanistic probe in physical organic chemistry for evaluating acyl-transfer pathways.
In biological systems, the concept of acetylurea extends beyond the isolated parent molecule to an entire family of pharmacophores. When lipophilic substituents, such as phenyl or alkyl groups, are appended to the acetyl backbone, the molecule readily crosses biological barriers, including the blood-brain barrier. The structural plasticity of the acyclic acylurea chain permits conformational freedom that cyclic counterparts, such as hydantoins or barbiturates, cannot achieve. This dynamic rotational flexibility allows acylurea derivatives to adopt bioactive conformations capable of selectively interacting with voltage-gated ion channels and metabolic enzymes within excitable neuronal tissues.
5. Historical Development
The chemical history of acetylurea begins in the golden era of nineteenth-century European organic chemistry. Following Wöhler's groundbreaking synthesis of urea in 1828, chemists across Germany, France, and Britain sought to explore the nucleophilic properties of urea by reacting it with diverse carboxylic acid derivatives. In 1854, the French chemist Charles Adolphe Wurtz, alongside contemporary researchers studying acyl chlorides, first reported the formation of mono-acetylated urea derivatives by treating dry urea with acetyl chloride. Subsequent refinements by Adolf von Baeyer in the 1860s—during his broader systematic investigations into uric acid and related ureides—established the precise stoichiometry and thermal behavior of acylurea condensation products.
Throughout the late nineteenth and early twentieth centuries, acetylurea remained largely a laboratory curiosity and a synthetic intermediate for synthesizing pyrimidines, purines, and substituted hydantoins. However, the pharmacological landscape shifted dramatically in the late 1930s and 1940s. Following the clinical discovery of phenytoin's anticonvulsant efficacy by H. Houston Merritt and Tracy Putnam in 1938, medicinal chemists realized that many successful antiepileptic agents possessed a common core: a central ring containing carbonyl and ureide groups flanked by aromatic rings. Researchers reasoned that opening the five-membered hydantoin ring might preserve or enhance anticonvulsant activity while minimizing sedation.
In 1949, Everett and Richards, working in collaboration with pharmaceutical laboratories, investigated open-chain analogs of hydantoins and synthesized phenylacetylurea, commercially known as phenacemide. Phenacemide represented a direct derivative of acetylurea in which a phenyl ring was appended to the alpha-carbon of the acetyl moiety. This breakthrough catapulted acetylureas into the forefront of clinical neurology, as phenacemide demonstrated unprecedented efficacy in controlling refractory psychomotor (complex partial) seizures. Over the subsequent decade, European investigators synthesized further structural variations, including ethylphenylacetylurea (pheneturide) and chlorphenacemide, solidifying the status of acetylureas as a pivotal milestone in the evolution of neurotherapeutics.
6. Theoretical Foundations
The study and application of acetylurea rest on foundational principles spanning physical organic chemistry, molecular conformation theory, and modern receptor-binding pharmacology. The primary theoretical model explaining the structure and stability of acetylurea is the resonance and molecular orbital model of amides and imides. In unsubstituted amides, resonance stabilization provides an energetic barrier to rotation about the C–N bond of approximately 15 to 20 kcal/mol. In acetylurea, the secondary nitrogen atom is flanked by two carbonyl groups, resulting in competing delocalization known as cross-conjugation. Theoretical calculations utilizing density functional theory (DFT) indicate that this competition diminishes the partial double-bond character of each individual C–N bond relative to a simple mono-amide, slightly lowering the rotational energy barrier while preserving significant planarity across the N–C(=O)–N–C(=O) spine.
A second theoretical framework critical to understanding acetylurea is the bioisosterism and ring-opening hypothesis of medicinal chemistry. Advanced by pioneers like Erlenmeyer and refined by Alfred Burger, bioisosteric replacement posits that molecules possessing similar spatial, electronic, and steric configurations can elicit comparable biological effects. Phenylacetylurea directly demonstrates this concept: opening the cyclic hydantoin ring (found in phenytoin) yields an acyclic acylurea chain that retains the essential pharmacophoric triad consisting of a hydrophobic aromatic group, hydrogen-bond-donating amide nitrogens, and hydrogen-bond-accepting carbonyl oxygens.
Pharmacodynamically, the therapeutic activity of acetylurea derivatives aligns with the classical Hodgkin-Huxley model of electrophysiology and modern structural biology of voltage-gated ion channels. Anticonvulsant acylureas act predominantly by stabilizing the inactive conformation of voltage-gated sodium channels (Nav channels). By binding selectively to the channel during high-frequency firing, these molecules prevent sustained repetitive neuronal depolarization without disrupting baseline neurological signaling. This state-dependent blockade represents a cornerstone of modern neuropharmacological theory.
7. Key Components, Types & Dimensions
Acetylurea can be broken down into specific chemical components, related chemical congeners, and structural dimensions that dictate its physicochemical and pharmacological profile:
- Core Structural Components:
- The Carbamoyl Fragment (–C(=O)NH2): Provides primary hydrogen bonding sites, conferring high crystalline stability and strong polarity.
- The Central Secondary Amide Linker (–NH–): Exhibits weakly acidic character due to flanking dicarbonyl groups, functioning as an indispensable hydrogen bond donor.
- The Acetyl Terminal (–C(=O)CH3): Supplies the second carbonyl oxygen for coordination and a methyl group capable of further chemical functionalization.
- Major Classification of Acylureas:
- Monosubstituted Acylureas: Linear compounds like parent acetylurea, where only a single acyl chain is attached to one nitrogen.
- Diacylureas (Symmetric and Asymmetric): Compounds in which both nitrogen atoms bear acyl groups, such as 1,3-diacetylurea, which exhibit lower aqueous solubility and altered melting dynamics.
- Alpha-Substituted Acylureas (Medicinal Acylureas): Clinically evaluated derivatives where the alpha-position of the acetyl moiety is substituted with lipophilic groups, such as phenacemide (2-phenylacetylurea), pheneturide (2-ethyl-2-phenylacetylurea), and chlorphenacemide.
- Cyclic Ureides: Closely related closed-ring systems formed through cyclization of acylurea precursors, encompassing barbiturates, hydantoins, and oxazolidinediones.
- Stereochemical and Tautomeric Dimensions:
- Amide-Iminol Tautomerism: While acetylurea exists predominantly in the keto-diamide form, prototropic tautomerism can produce trace enol/iminol forms that participate in specialized transition-state reactions.
- Conformational Rotamers: Freedom of rotation about the C(acyl)–N and C(urea)–N bonds generates distinctive cis/trans (or syn/anti) conformers, with the trans-trans arrangement exhibiting maximum intermolecular stabilization in the solid state.
8. Examples & Illustrative Cases
To contextualize acetylurea within practical science and medicine, several real-world examples and clinical historical cases illustrate its synthesis, derivative applications, and pharmacological outcomes:
Example 1: Classical Laboratory Synthesis of Parent Acetylurea
In synthetic organic methodology, acetylurea is conventionally prepared through the condensation of anhydrous urea with acetic anhydride in the presence of a catalytic amount of concentrated sulfuric acid. The reaction mixture is heated to approximately 80–90 °C for several hours, driving the electrophilic attack of the acyl carbon on the urea nitrogen. Upon cooling, the crude product precipitates as a dense white crystalline mass, which is recrystallized from boiling water or absolute ethanol to yield pure N-acetylurea with a sharp melting point of 218 °C. This reaction demonstrates the nucleophilic versatility of urea despite its resonance-delocalized electron pairs.
Case Illustration 1: Clinical Deployment of Phenacemide in Intractable Epilepsy
During the 1950s, a 34-year-old patient presented with severe, medically refractory psychomotor seizures that failed to respond to therapeutic doses of phenobarbital and diphenylhydantoin. The treating neurologist initiated therapy with phenacemide, an alpha-phenyl substituted derivative of acetylurea, titrated up to 1.5 grams daily. The patient experienced a dramatic cessation of seizure activity, entering complete clinical remission for six months. However, routine laboratory monitoring subsequently revealed elevated serum transaminases and mild jaundice, accompanied by acute depressive psychosis. The medication was promptly withdrawn, illustrating both the remarkable therapeutic potency and the severe hepatotoxic and psychiatric risks that ultimately constrained the clinical utilization of open-chain acetylureas.
Example 2: Acetylurea as a Precursor in Pyrimidine Synthesis
In heterocyclic industrial manufacturing, acetylurea serves as an intermediate in the condensation synthesis of methyl-substituted pyrimidinediones. Reacting acetylurea with active methylene compounds, such as diethyl malonate under basic sodium ethoxide catalysis, permits ring closure through tandem nucleophilic addition-elimination reactions. This synthetic route highlights how the pre-assembled dicarbonyl-urea backbone of acetylurea streamlines the construction of complex nitrogenous heterocycles utilized in agrochemicals and dyes.
9. Measurement & Assessment
The identification, quantitative determination, and structural characterization of acetylurea and its related derivatives rely on modern spectroscopic, chromatographic, and thermal analytical methodologies:
In analytical chromatography, High-Performance Liquid Chromatography (HPLC) coupled with ultraviolet (UV) detection or tandem mass spectrometry (LC-MS/MS) represents the gold standard for separating and quantifying acetylurea in reaction mixtures and biological specimens. Reversed-phase C18 columns utilizing isocratic or gradient elution of water and acetonitrile (often buffered with 0.1% formic acid) provide sharp chromatographic peaks. Detection via UV spectrophotometry typically targets the low wavelength region (around 205 to 215 nm), corresponding to π → π* electronic transitions within the amide and urea carbonyl chromophores.
Nuclear Magnetic Resonance (NMR) spectroscopy provides definitive structural identification. In proton NMR (1H-NMR) using deuterated dimethyl sulfoxide (DMSO-d6), acetylurea produces distinct characteristic signals: a sharp singlet corresponding to the three methyl protons of the acetyl group at approximately δ 2.05 ppm, a broad two-proton resonance representing the primary carbamoyl –NH2 group around δ 7.20–7.50 ppm, and a downfield, exchangeable singlet for the secondary –NH– proton appearing near δ 10.10–10.30 ppm. In carbon-13 NMR (13C-NMR), three well-resolved resonance peaks emerge: the methyl carbon at δ ~24 ppm, the carbamoyl carbonyl carbon at δ ~154 ppm, and the acetyl carbonyl carbon at δ ~172 ppm.
Infrared (IR) spectroscopy remains an essential diagnostic tool for identifying the functional groups of acetylurea. Characteristic vibrational absorption bands include strong N–H stretching frequencies between 3350 and 3180 cm−1, indicating extensive hydrogen bonding. The carbonyl region displays two pronounced, closely spaced "Amide I" bands near 1690 cm−1 and 1660 cm−1, corresponding respectively to the acetyl carbonyl and the urea carbonyl stretchings. Thermal analysis using Differential Scanning Calorimetry (DSC) displays a sharp, endothermic melting transition at 218–220 °C, verifying crystalline purity without decomposition prior to the melting point.
10. Applications & Practical Significance
Although parent acetylurea is not commonly administered today as a frontline active pharmaceutical ingredient, its practical, technological, and conceptual applications across multiple scientific sectors remain highly consequential:
Medicinal Chemistry and Pharmacophore Modeling:
The primary significance of acetylurea lies in its role as the prototype for open-chain ureide therapeutics. It demonstrated to medicinal chemists that rigid heterocyclic rings are not strictly mandatory for eliciting central nervous system depressant and anticonvulsant effects. Studying acetylurea analogues paved the way for modern flexible drug designs, where conformational entropy is balanced against target-binding affinity to optimize drug bioavailability and selectivity.
Organic Synthesis and Industrial Precursor Chemistry:
Acetylurea functions as an efficient mono-nitrogen and dicarbonyl donor in the synthesis of diverse heterocyclic molecules, including hydantoins, triazoles, and pyrimidines. Its relative stability and safety compared to hazardous reagents like phosgene or volatile isocyanates make it an attractive synthons in fine chemical manufacturing, specialized plasticizer development, and agricultural synthesis of slow-release nitrogen formulations.
Crystallography and Materials Science:
In the study of supramolecular chemistry and crystal engineering, acetylurea serves as an archetypal model for exploring self-assembly mediated by complementary hydrogen-bonding motifs. Because it contains both donor and acceptor sites within a short, compact carbon-nitrogen backbone, researchers use acetylurea to investigate crystal growth kinetics, polymorphism, and co-crystallization phenomena relevant to developing energetic materials and advanced pharmaceutical co-crystals.
11. Research & Empirical Evidence
Scientific literature surrounding acetylurea and its immediate congeners spans several decades, progressing from early empirical animal screening to contemporary toxicological and structural investigations.
In the seminal laboratory studies conducted by Everett, Richards, and Smith in the late 1940s and early 1950s, various aliphatic and aromatic acylureas were systematically evaluated in rodent models of generalized and partial seizures, specifically utilizing the maximal electroshock seizure (MES) test and the subcutaneous pentylenetetrazol (Metrazol) seizure threshold test. Their published data demonstrated that while parent acetylurea showed weak protective activity, the introduction of a phenyl group (phenacemide) or an ethyl and phenyl group (pheneturide) dramatically elevated the protective index, exhibiting potencies superior to both phenobarbital and phenytoin in elevating psychomotor seizure thresholds.
Subsequent toxicological investigations conducted by Gibbs, Tyler, and colleagues delineated the clinical hazards associated with long-term administration of substituted acetylureas. Their comprehensive empirical studies documented that between 15% and 25% of patients treated with phenacemide developed severe toxic side effects, including severe personality changes, psychoses, toxic hepatitis, aplastic anemia, and acute nephritis. These findings spurred medicinal chemistry efforts to identify the exact biotransformation pathways responsible for such adverse reactions. Modern metabolic studies have demonstrated that hepatic cytochrome P450 enzymes metabolize open-chain acylureas into reactive electrophilic intermediates, including reactive arene oxides and isocyanate species, which covalently bind to cellular macromolecules and induce immune-mediated organ damage.
In contemporary crystallographic and computational research, investigators utilizing high-resolution X-ray diffraction and quantum chemical simulations have mapped the electron density distribution of acetylurea. Studies published by crystal engineering consortia confirmed that acetylurea exhibits extraordinary cooperative hydrogen bonding, demonstrating that the formation of primary amide dimers significantly enhances the polarization and subsequent hydrogen bonding strength of the secondary imide nitrogen.
12. Cultural & Cross-Cultural Considerations
The cultural and historical context of acetylurea derivatives reflects differing cross-national attitudes toward pharmaceutical risk tolerance and regulatory oversight during the mid-twentieth century. Following the Second World War, the global medical community faced an urgent need to treat profound trauma-induced epilepsy and severe refractory seizure disorders that left patients heavily institutionalized.
In the United States, the Food and Drug Administration (FDA) approved phenacemide in 1949 under strict "drug of last resort" labeling due to recognized toxicities. American clinical culture approached the drug with extreme caution, mandating rigorous weekly or monthly blood counts and hepatic function testing. Conversely, in several European nations—including the United Kingdom, France, and Germany—clinicians favored alternative derivatives such as pheneturide (known commercially as Benuride or Trinuride) and chlorphenacemide. European clinical consensus viewed pheneturide as having a marginally safer therapeutic index, leading to its widespread use in multi-drug antiepileptic regimens throughout the 1960s and 1970s.
Furthermore, the linguistic and administrative evolution of chemical nomenclature across different linguistic zones (e.g., British Pharmacopoeia versus United States Pharmacopeia) influenced how acylureas were categorized. In Western medical discourse, the tragic toxicities associated with acylureas contributed directly to the establishment of modern pharmacovigilance protocols and stricter phase-based clinical trial mandates, permanently altering how clinical risks and therapeutic benefits are balanced internationally.
13. Criticisms, Debates & Limitations
The primary controversy and clinical debate surrounding the acetylurea class centers upon their prohibitive risk-to-benefit ratio and unpredictable idiosyncratic toxicities. While open-chain acylureas demonstrated exceptional, often unparalleled efficacy against focal seizures with impaired awareness (psychomotor epilepsy) where classic hydantoins and barbiturates routinely failed, their clinical utility was severely undermined by fatal organ toxicities.
The debate among mid-century epileptologists was characterized by two competing philosophies: one school of thought argued that the complete cessation of debilitating seizures justified the risk of catastrophic liver failure or aplastic anemia under intensive monitoring, while the opposing faction asserted that introducing potentially lethal or psychosis-inducing compounds into vulnerable populations was clinically unethical. The emergence of modern, far safer broad-spectrum anticonvulsants—beginning with carbamazepine and sodium valproate in the 1960s and 1970s, and followed by modern second- and third-generation agents like lamotrigine and levetiracetam—effectively settled the debate, rendering therapeutic acetylureas virtually obsolete in contemporary clinical neurology.
Another scientific critique involves the inherent metabolic instability of the acylurea linkage. Because the central nitrogen is acylated, the molecule remains vulnerable to both enzymatic amidase cleavage and spontaneous hydrolytic degradation. In industrial synthetic applications, attempts to use acetylurea as a green agrochemical nitrogen source faced limitations due to unpredictable environmental mineralization rates, where abiotic hydrolysis often outpaced bacterial enzymatic utilization under varying soil moisture and pH conditions.
14. Related Terms & Distinctions
To ensure clarity in chemical and pharmacological discourse, acetylurea must be rigorously distinguished from several related chemical classes and structural analogues:
- Urea: The parent diamide of carbonic acid (NH2CONH2). Lacks the acetyl moiety; possesses higher water solubility, lower melting point (133 °C), and functions predominantly as a nitrogenous metabolic waste product and industrial fertilizer rather than a synthetic acylating framework.
- Phenacemide (Phenylacetylurea): A direct structural analogue of acetylurea where a phenyl group is substituted at the alpha-carbon. Unlike parent acetylurea, phenacemide is a potent anticonvulsant agent, historically used for complex partial seizures but associated with severe hepatotoxicity.
- Pheneturide (Ethylphenylacetylurea): A disubstituted analogue carrying both an ethyl and a phenyl group on the acetyl backbone. Displays enhanced lipophilicity and anticonvulsant activity compared to acetylurea and phenacemide, formerly prescribed widely in Europe.
- Hydantoins (e.g., Phenytoin): Five-membered heterocyclic rings containing a glycolylurea core. Hydantoins represent the cyclic structural counterparts of acylureas; closing the chain between the alpha-carbon and the terminal nitrogen yields a hydantoin ring, which typically exhibits lower psychiatric toxicity.
- Barbiturates (e.g., Phenobarbital): Six-membered cyclic ureides derived from malonylurea. While sharing the urea-carbonyl structural motifs of acetylurea, barbiturates act predominantly via allosteric potentiation of GABAA receptors, producing profound sedation and hypnosis that open-chain acetylureas generally do not induce at therapeutic doses.
- Acetamide: The simplest monocarboxylic acid amide (CH3CONH2). Lacks the carbamoyl (–CONH2) unit present in acetylurea, possessing a much lower melting point (80 °C) and markedly different hydrogen-bonding geometry.
15. Summary / Key Takeaways
Acetylurea is a classic organic compound that represents the simplest aliphatic acylurea, structurally uniting an acetyl group with a urea scaffold. With a chemical formula of C3H6N2O2, it forms highly stable crystals characterized by extensive intermolecular hydrogen bonding networks and a high melting point around 219 °C. While parent acetylurea possesses negligible direct therapeutic value, its discovery and structural modification unlocked a critical historical era in pharmacology, culminating in the development of open-chain anticonvulsants like phenacemide and pheneturide that proved crucial for understanding seizure management and state-dependent sodium channel blockade.
Ultimately, the legacy of acetylurea resides in its immense contributions to fundamental chemical theory and drug design. It served as a quintessential example of bioisosterism, showing how acyclic molecules could emulate the therapeutic profiles of cyclic scaffolds such as hydantoins. Concurrently, the severe toxicological hurdles encountered by its clinical derivatives spurred modern pharmacovigilance and revolutionized our understanding of drug metabolism and reactive intermediates. Today, acetylurea endures as an essential chemical building block in heterocyclic synthesis, crystallographic modeling, and mechanistic organic chemistry.
References
- Everett, G. M., & Richards, R. K. (1952). Pharmacological studies of phenacemide (phenurone), an anticonvulsant drug. Journal of Pharmacology and Experimental Therapeutics, 106(3), 303–313.
- Gibbs, F. A., Everett, G. M., & Richards, R. K. (1949). Phenurone in epilepsy. Diseases of the Nervous System, 10(2), 47–49.
- Lien, E. J., & Hussain, M. (1970). Structure-activity relationship of open-chain acylureas and related compounds as central nervous system agents. Journal of Medicinal Chemistry, 13(4), 628–632. https://doi.org/10.1021/jm00298a011
- Livingston, S., & Boks, L. L. (1955). Use of the open-chain ureide phenacemide in the treatment of epilepsy. The New England Journal of Medicine, 252(20), 856–859. https://doi.org/10.1056/NEJM195505192522005
- Pfeiffer, C. C., & Jenney, E. H. (1954). The pharmacology and clinical trials of substituted acylureas. Annals of the New York Academy of Sciences, 58(4), 481–492.
- Talarico, C. P., & Nelson, W. L. (1981). Synthesis, stereochemistry, and anticonvulsant activity of acyclic ureides related to phenacemide. Journal of Pharmaceutical Sciences, 70(7), 808–812. https://doi.org/10.1002/jps.2600700728